Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1038/nutd.2016.37 http://scihub22266oqcxt.onion/10.1038/nutd.2016.37 C5022149!5022149!27571249     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 245.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Nutr+Diabetes 2016 ; 6 (8): e228- Nephropedia Template TP {{tp|p=27571249|t=2016. Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial |pdf=|usr=}}{{27571249}} gab.com Text Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial JO: Nutr Diabetes http://www.kidney.de/pget.php?&tw=1&pmid=27571249 #FOAvip Background:: As adolescents with obesity and insulin resistance may be refractory to lifestyle intervention therapy alone, additional off-label metformin therapy is often used. In this study, the long-term efficacy and safety of metformin versus placebo in adolescents with obesity and insulin resistance is studied. Methods:: In a randomized placebo-controlled double-blinded trial, 62 adolescents with obesity aged 10?16 years old with insulin resistance received 2000?mg of metformin or placebo daily and physical training twice weekly over 18 months. Primary end points were change in body mass index (BMI) and insulin resistance measured by the Homeostasis Model Assessment for Insulin Resistance (HOMA-IR). Secondary end points were safety and tolerability of metformin. Other end points were body fat percentage and HbA1c. Results:: Forty-two participants completed the 18-month study (66% girls, median age 13 (12?15) years, BMI 30.0 (28.3 to 35.0) kg?m?2 and HOMA-IR 4.08 (2.40 to 5.88)). Median ?BMI was +0.2 (?2.9 to 1.3) kg?m?2 (metformin) versus +1.2 (?0.3 to 2.4) kg?m?2 (placebo) (P=0.015). No significant difference was observed for HOMA-IR. No serious adverse events were reported. Median change in fat percentage was ?3.1 (?4.8 to 0.3) versus ?0.8 (?3.2 to 1.6)% (P=0.150), in fat mass ?0.2 (?5.2 to 2.1) versus +2.0 (1.2?6.4) kg (P=0.007), in fat-free mass +2.0 (?0.1 to 4.0) versus +4.5 (1.3 to 11.6) kg (P=0.047) and in ?HbA1c +1.0 (?1.0 to 2.3) versus +3.0 (0.0 to 5.0) mmol?mol?1 (P=0.020) (metformin versus placebo). Conclusions:: Long-term treatment with metformin in adolescents with obesity and insulin resistance results in stabilization of BMI and improved body composition compared with placebo. Therefore, metformin may be useful as an additional therapy in combination with lifestyle intervention in adolescents with obesity and insulin resistance. Twit Text FOAVip Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial ????Nutr Diabetes http://www.kidney.de/pget.php?&tw=1&pmid=27571249 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27571249 #FOAvip English Wikipedia <ref>{{Cite pmid|27571249}}</ref> Long-term treatment with metformin in obese, insulin-resistant adolescents: results of a randomized double-blinded placebo-controlled trial #MMPMID27571249 van der Aa MP; Elst MAJ; van de Garde EMW; van Mil EGAH; Knibbe CAJ; van der Vorst MMJ Nutr Diabetes 2016[Aug]; 6 (8): e228- PMID27571249show ga Background:: As adolescents with obesity and insulin resistance may be refractory to lifestyle intervention therapy alone, additional off-label metformin therapy is often used. In this study, the long-term efficacy and safety of metformin versus placebo in adolescents with obesity and insulin resistance is studied. Methods:: In a randomized placebo-controlled double-blinded trial, 62 adolescents with obesity aged 10?16 years old with insulin resistance received 2000?mg of metformin or placebo daily and physical training twice weekly over 18 months. Primary end points were change in body mass index (BMI) and insulin resistance measured by the Homeostasis Model Assessment for Insulin Resistance (HOMA-IR). Secondary end points were safety and tolerability of metformin. Other end points were body fat percentage and HbA1c. Results:: Forty-two participants completed the 18-month study (66% girls, median age 13 (12?15) years, BMI 30.0 (28.3 to 35.0) kg?m?2 and HOMA-IR 4.08 (2.40 to 5.88)). Median ?BMI was +0.2 (?2.9 to 1.3) kg?m?2 (metformin) versus +1.2 (?0.3 to 2.4) kg?m?2 (placebo) (P=0.015). No significant difference was observed for HOMA-IR. No serious adverse events were reported. Median change in fat percentage was ?3.1 (?4.8 to 0.3) versus ?0.8 (?3.2 to 1.6)% (P=0.150), in fat mass ?0.2 (?5.2 to 2.1) versus +2.0 (1.2?6.4) kg (P=0.007), in fat-free mass +2.0 (?0.1 to 4.0) versus +4.5 (1.3 to 11.6) kg (P=0.047) and in ?HbA1c +1.0 (?1.0 to 2.3) versus +3.0 (0.0 to 5.0) mmol?mol?1 (P=0.020) (metformin versus placebo). Conclusions:: Long-term treatment with metformin in adolescents with obesity and insulin resistance results in stabilization of BMI and improved body composition compared with placebo. Therefore, metformin may be useful as an additional therapy in combination with lifestyle intervention in adolescents with obesity and insulin resistance. äLong-term treatment with metformin in obese, insulin-resistant adolesc(epmc).pdf DeepDyve Pubget Overpricing